# Long-Lasting Myocardial and Skeletal Muscle Damage Evidenced by Serial CMR During the First Year in COVID-19 Patients From the First Wave

Laura Filippetti, Nathalie Pace, Jean-Sebastien Louis, Damien Mandry, François Goehringer, Maria-Soledad Rocher, Nicolas Jay, Christine Selton-Suty, Gabriela Hossu, Olivier Huttin, et al.

► To cite this version:

Laura Filippetti, Nathalie Pace, Jean-Sebastien Louis, Damien Mandry, François Goehringer, et al. Long-Lasting Myocardial and Skeletal Muscle Damage Evidenced by Serial CMR During the First Year in COVID-19 Patients From the First Wave. Frontiers in Cardiovascular Medicine, 2022, 9, pp.831580. 10.3389/fcvm.2022.831580. [hal-03933697](https:// HAL Id: hal-03933697 )

https://inria.hal.science/hal-03933697

Submitted on 10 Jan 2023

**HAL** is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
<figure><img src="image_2.png" /></figure>

# Long-Lasting Myocardial and Skeletal Muscle Damage Evidenced by Serial CMR During the First Year in COVID-19 Patients From the First Wave

Laura Filippetti<fnref n="1" />*, Nathalie Pace<fnref n="1" />, Jean-Sebastien Louis²,<fnref n="3" />, Damien Mandry²,⁴, François Goehringer⁵, Maria-Soledad Rocher<fnref n="6" />, Nicolas Jay<fnref n="6" />, Christine Selton-Suty<fnref n="1" />, Gabriela Hossu²,<fnref n="3" />, Olivier Huttin<fnref n="1" />,⁷ and Pierre-Yves Marie⁷,⁸

**OPEN ACCESS**

**Edited by:**
Carlo Gabriele Tocchetti,
University of Naples Federico II, Italy

**Reviewed by:**
Lu Huang,
Huazhong University of Science and
Technology, China
Alessandro Pingitore,
Clinical Physiology Institute, CNR, Italy

*Correspondence:
Laura Filippetti
l.filippetti@chru-nancy.fr

**Specialty section:**
This article was submitted to Cardiovascular Imaging, a section of the journal Frontiers in Cardiovascular Medicine

**Received:** 08 December 2021
**Accepted:** 15 February 2022
**Published:** 09 March 2022

**Citation:**
Filippetti L, Pace N, Louis J-S, Mandry D, Goehringer F, Rocher M-S, Jay N, Selton-Suty C, Hossu G, Huttin O and Marie P-Y (2022) Long-Lasting Myocardial and Skeletal Muscle Damage Evidenced by Serial CMR During the First Year in COVID-19 Patients From the First Wave. Front. Cardiovasc. Med. 9:831580. doi: 10.3389/fcvm.2022.831580

**Introduction:** This observational CMR study aims to characterize left-ventricular (LV) damage, which may be specifically attributed to COVID-19 and is distant in time from the acute phase, through serial CMR performed during the first year in patients with no prior cardiac disease.

**Methods:** This study included consecutive patients without any prior history of cardiac disease but with a peak troponin-Ic > 50 ng/ml at the time of the first COVID-wave. All had a CMR in the first months after the acute phase, and some had an additional CMR at the end of the first year to monitor LV function, remodeling, and abnormalities evocative of myositis and myocarditis - i.e., increased T1/T2 relaxation times, increased extracellular volume (ECV), and delayed contrast enhancement.

**Results:** Nineteen consecutively admitted COVID-19 patients (17 men, median age 66 [57–71] years) were included. Eight (42%) had hypertension, six (32%) were obese, and 16 (84%) had suffered an acute respiratory distress syndrome. The 1st CMR, recorded at a median 3.2 [interquartile range: 2.6–3.9] months from the troponin peak, showed (1) LV concentric remodeling in 12 patients (63%), (2) myocardial tissue abnormalities in 11 (58%), including 9 increased myocardial ECVs, and (3) 14 (74%) increased ECVs from shoulder skeletal muscles. The 2nd CMR, obtained at 11.1 [11.0–11.7] months from the troponin peak in 13 patients, showed unchanged LV function and remodeling but a return to normal or below the normal range for all ECVs of the myocardium and skeletal muscles.

**Conclusion:** Many patients with no history of cardiac disease but for whom an increase in blood troponin-Ic ascertained COVID-19 induced myocardial damage exhibited signs

<footnote n="1">¹Department of Cardiology, CHRU-Nancy, Nancy, France, ²Université de Lorraine, INSERM, UMR-1254, Nancy, France,</footnote>

<footnote n="3">³CHRU-Nancy, Université de Lorraine, CIC 1433, Nancy, France, ⁴Department of Radiology, CHRU-Nancy, Université de Lorraine, Nancy, France, ⁵Department of Infectious Diseases, CHRU-Nancy, Université de Lorraine, Nancy, France.</footnote>

<footnote n="6">⁶Department of Medical Information, CHRU-Nancy, Université de Lorraine, Nancy, France, ⁷Université de Lorraine, INSERM, UMR-1116, Nancy, France, ⁸CHRU-Nancy, Université de Lorraine, Nuclear Medicine and Nancyclotep Platform, Nancy, France</footnote>
of persistent extracellular edema at a median 3-months from the troponin peak, affecting
the myocardium and skeletal muscles, which resolved within a one-year time frame.
Associations with long-COVID symptoms need to be investigated on a larger scale now.

**Clinical Trial Registration:** NCT04753762 on the ClinicalTrials.gov site.

**Keywords:** COVID-19, myocarditis, edema, skeletal muscle, cardiovascular magnetic resonance imaging

# INTRODUCTION

COVID-19 induced myocardial damage is complex and
exhibits features consistent with inflammation and endothelium
dysfunction, and thrombosis (1–3). It has been speculated
that this myocardial damage might constitute a risk factor for
developing heart failure, given the similarities in the profiles of
patients at risk of heart failure with those of severe COVID-19
patients (4). There is, therefore, an urgent need to specify the
nature of COVID-19 induced myocardial damage and investigate
its impact over time.

Cardiac Magnetic Resonance (CMR) already documented
myocardial tissue abnormalities at the acute or sub-acute phase
of COVID-19 and, more specifically, increases in myocardial T1
and T2 relaxation times and an increased extracellular volume
(ECV) (5, 6). This observation was at the time attributed to
inflammatory edema. However, we do not yet know what the
clinical consequences of these anomalies are in the long term and
whether they correspond to a COVID-19 pathology specifically
targeted to the heart or to a more diffuse edematous and
inflammatory response (7). Myositis with skeletal muscle edema
is also frequently observed during COVID-19 (8).

This observational CMR study aims to characterize the left-
ventricular (LV) damage which may be specifically attributed to
COVID-19 and distant in time from the acute phase, through
serial CMR planned during the first year in patients with
no previous history of cardiac disease but with significant
increases in blood troponin-Ic during the initial COVID-
19 hospitalization.

# MATERIALS AND METHODS

## Patients and Study Design

The study included consecutive 18- to 80-year-old patients
hospitalized in our Regional University Hospital for a COVID-
19-related pathology between the 16th and the 31st of March
2020, which corresponded to the peak of the first COVID-19
wave in our region. Patients' COVID-19 status was ascertained
by a positive reverse transcriptase-polymerase chain reaction
test. Additional inclusion criteria were: (i) a peak troponin Ic
> 50 ng/ml measured during hospitalization, (ii) the absence
of any prior cardiac disease history, and (iii) health conditions
required to endure the CMR-based monitoring which is currently
prescribed for myocarditis patients in our center.

Baseline investigations were performed with the 1st CMR
within the first months following the acute phase and the follow-
up investigations with the 2nd CMR, at the end of the first
year, on a 3T PRISMA Magnet (Siemens Medical Solutions,

Erlangen, Germany). Echocardiography and blood analysis for
routine biomarkers were also performed on the CMR days.
Echocardiography data were obtained according to current
recommendations (9, 10) with a General Electric® device and the
post-processing EchoPAC® software.

## CMR Recording

The same CMR protocol was used in all patients and for both the
1st and 2nd CMR. LV function and remodeling were assessed on
cine images recorded with a compressed sensing SSFP sequence
(11), on contiguous short-axis slices and with the following
parameters: 2 x 2 x 8 mm³ voxel size, 420 x 320 mm² field of view
(FOV), 60° flip angle (FA), 41 ms repetition time (TR), 2.9 ms
interecho time, 1.27 ms echo time (TE), and 14 segments.

According to the “2018 updated Lake Louise Criteria” (12),
signs of myocarditis were searched for (i) on longitudinal (T1)
and transversal (T2) relaxation maps recorded with short-axis
slices and, respectively, precontrast - Modified Look-Locker
Inversion Recovery (MOLLI, acquisition scheme 5(3)3) and
2D TurboFlash sequences (12), and (ii) on contiguous late
gadolinium enhancement images covering the LV on short-axis,
vertical and horizontal long-axis directions with a fast multi-slice
phase-sensitive inversion recovery sequence (13), 10 to 15 min
after the injection of 0.1 mmol.kg⁻¹ body weight of Dotarem®,
(GUERBET, France). T1 maps were recorded with the following
parameters: 1.4 x 1.4 x 8.0 mm³ voxel size, 371 x 278 mm² FOV,
35° FA, 1 excitation, 180 ms time to inversion (TI), 267 ms TR,
1.11 ms TE, and 63 segments. For the T2 maps, these parameters
were: 1.9 x 1.9 x 8.0 mm³ voxel size, 360 x 360 mm² FOV,
12° FA, 201 ms TR, and 1.32/30/50 ms TE. For the LGE images,
these parameters were: 2.1 x 2.1 x 8 mm³ voxel size, 400 x 380
mm² FOV, 40° FA, 305 ms TI, 768 ms RT, 2.4 ms interecho time,
1.04 ms TE, and 1 excitation.

## CMR Analysis

CMR results were extracted with the Syngovia software (Siemens
Medical Solutions, Erlangen, Germany), using a manual
adjustment of the ventricular contours applied to determine
LV mass, end-diastolic volumes, and ejection fractions (14).
Ventricular volumes and LV mass were indexed to body surface
area, and the LV mass/end-diastolic volume ratio was used to
assess LV concentric remodeling (15, 16). Myocardial T1 and
T2 were determined with regions of interest (ROI) drawn on
a septal mid-ventricular area (Figure 1) (17). The myocardial
extracellular volume (ECV), expressed as % myocardium volume,
was conventionally computed from: (i) T1-pre values from
the pre-contrast MOLLI sequence described above (ii) T1-
post values from post-contrast MOLLI sequence (acquisition
<figure><img src="image_3.png" /><figcaption>**FIGURE 1** | Pre-contrast T1 map showing regions-of-interest (ROIs) drawn to determine ECV and relaxation times on the myocardium (blue) and shoulders skeletal muscle (red).</figcaption></figure>

scheme: 4(1)3(1)2) acquired 10–15 min after the injection and (iii) individual hematocrit values (6, 12). The latter were obtained from blood sampled just before CMR, during placement of the intravenous catheter used for Dotarem® injection.

The cardiac T1 maps were additionally used to determine the T1 and ECV of the shoulder skeletal muscles setting in the field of view (i.e., the pectoralis major, subscapularis, or infraspinatus) with careful exclusion of perimuscular fat and intramuscular tendons from the hand-drawn ROIs (Figure 1), as previously described (17).

## Criteria Used to Define Abnormal CMR Parameters

Normal limits for the main CMR parameters are summarized in Table 1. Most of these normal limits were derived from the 95% confidence intervals and obtained from local control populations with the same operator and extraction methods as the current COVID-19 study.

Normal values of LV ejection fraction, mass, volume, and mass/volume ratio, which are used to assess LV function and remodeling, and which are known to vary according to age and sex, were extracted from a local database of patients without any known cardiovascular disease (14). The final population was further selected according to age to provide a comparable mean and distribution to our COVID-19 population (for mean ± SD: 64.2 ± 7.5 vs. 64.2 ± 8.3 years). There were 74 men and 84 women with respective lower limits of 49% and 51% LV ejection fraction, and respective upper limits of 97 and 88 mL.m⁻² for LV end-diastolic volume, 73 and 57 g.m⁻² for LV mass, and 1.11 and 0.90 for LV mass/volume ratio. These limits are within the range of those already defined for ≥ 60 years old normal subjects in previously published CMR studies (18–20).

<table><caption>**TABLE 1** | Limits used to define abnormal values for the main CMR parameters obtained from local control populations with the same operator and extraction methods as the current COVID-19 study.</caption><thead><tr><th></th><th>Women</th><th>Men</th></tr></thead><tbody><tr><td>Lower LV ejection fraction limits</td><td>51 %</td><td>49 %</td></tr><tr><td>Upper LV mass limits</td><td>57 g/m²</td><td>73 g/m²</td></tr><tr><td>Upper limits for LV mass/volume ratio</td><td>0.90</td><td>1.11</td></tr><tr><td>Upper myocardial T1 limits</td><td>1,293 ms</td><td>1,293 ms</td></tr><tr><td>Upper myocardial T2 limits</td><td>47 ms</td><td>47 ms</td></tr><tr><td>Upper myocardial ECV limits</td><td>28.5 %</td><td>28.5 %</td></tr><tr><td>Upper skeletal T1 limits</td><td>1,206 ms</td><td>1,206 ms</td></tr><tr><td>Upper skeletal ECV limits</td><td>14.9 %</td><td>14.9 %</td></tr></tbody></table>

ECV, extracellular volume, LV, left ventricle, T1, longitudinal relaxation time, T2, transversal relaxation time.

Normal T1 and ECV values were determined for both myocardium and shoulders skeletal muscles in a population extracted from a local database of patients who had been initially investigated for a mitral valve prolapse (21). The final selection only included patients without any complicated prolapse (absence of ≥ 2 mitral regurgitation, ventricular arrhythmias, or LV dysfunction) and without any other cardiovascular disease. This group included 30 subjects, 11 women and 19 men, with a mean age of 40 ± 18 years. The normal upper limits of T1 were computed as 1,293 ms for the myocardium and 1,206 ms for the skeletal shoulder muscles. For normal ECV, the respective upper limits were 28.5 and 14.9%. These limits are very similar to those obtained in previous CMR studies performed using a comparable methodology (22, 23).

For myocardial T2, we selected the threshold of 47 ms which corresponds to the upper limit of the 95% confidence interval observed in a study performed with a 3T magnet and with the same methodology as that used in our COVID-19 patients (24).

Late gadolinium enhancement was identified visually by a single observer (PM) as an increase in the signal from myocardial areas clearly distinct from the epicardial fat and cavitary blood. All transmural or sub-epicardial areas of LGE were considered as potentially related to myocarditis (14). This was not the case for the LGE evocative of a mid-wall septal fibrosis and commonly associated with LV hypertrophy and remodeling in the absence of any myocarditis (25).

## Statistical Analysis

Statistical analyses were obtained using the SPSS statistical software (IBM Statistics version 20). Qualitative variables were expressed as numbers and percentages and quantitative variables were expressed as medians with interquartile ranges. As the number of cases was not sufficiently large to assume a normal distribution, paired comparisons of quantitative variables between the two CMR visits were assessed using a non-parametric test: the Wilcoxon sum-rank test. Paired comparisons of qualitative variables were planned with Mc Nemar tests. P values were not adjusted for possible multiple comparison
<table><caption>**TABLE 2** | Main characteristics of the 19 patients with blood, clinical and CMR data collected on the day of the 1st CMR, at a median of 3.2 months from the troponin peak.</caption><thead><tr><th>Age (years)</th><th>66 [59-71]</th></tr></thead><tbody><tr><td>Female</td><td>2 (11%)</td></tr><tr><td>Diabetes</td><td>7 (37%)</td></tr><tr><td>Dyslipidemia</td><td>6 (32%)</td></tr><tr><td>Hypertension</td><td>8 (42%)</td></tr><tr><td>Obesity (BMI > 30 kg/m²)</td><td>7 (37%)</td></tr><tr><td>ARDS at acute phase</td><td>16 (84%)</td></tr><tr><td>Peak troponin Ic at acute phase (ng/ml)</td><td>242 [83-896]</td></tr><tr><td>Delay time from peak Troponin (months)</td><td>3.2 [2.6-3.9]</td></tr><tr><td>Heart rate (bpm)</td><td>80.0 [64.8-82.1]</td></tr><tr><td>Systolic BP (mmHg)</td><td>134 [132-155]</td></tr><tr><td>Diastolic BP (mmHg)</td><td>81 [72-85]</td></tr><tr><td>End-diastolic LV volume (mL/m²)</td><td>63 [55-72]</td></tr><tr><td>LV ejection fraction (%)</td><td>58 [52-65]</td></tr><tr><td>LV mass (g/m²)</td><td>70 [59-80]</td></tr><tr><td>LV mass / volume ratio</td><td>1.20 [0.91-1.27]</td></tr><tr><td>End-diastolic RV volume (mL/m²)</td><td>56 [53-68]</td></tr><tr><td>RV ejection fraction (%)</td><td>55 [51-59]</td></tr><tr><td>Myocardial T1 (ms)</td><td>1,257 [1,221-1,270]</td></tr><tr><td>Myocardial T2 (ms)</td><td>38.0 [36.0-40.2]</td></tr><tr><td>Myocardial ECV (%)</td><td>27.6 [25.4-31.5]</td></tr><tr><td>Delayed retention myocarditis pattern</td><td>2 (11%)</td></tr><tr><td>Skeletal T1 (ms)</td><td>1,149 [1,110-1,149]</td></tr><tr><td>Skeletal ECV (%)</td><td>16.5 [14.4-22.4]</td></tr><tr><td>Hematocrit (%)</td><td>42.4 [40.3-43.9]</td></tr><tr><td>C Reactive Protein (mg/mL)</td><td>4 (4)</td></tr><tr><td>Troponin Ic (ng/ml)</td><td>6.0 [2.0-13.0]</td></tr><tr><td>Nt-pro BNP (pg/mL)</td><td>111 [36-259]</td></tr><tr><td>Albumin (g/L)</td><td>41.5 [39.1-46.4]</td></tr><tr><td>eGFR (ml/min/1.73 m²)</td><td>90 [84-90]</td></tr></tbody></table>

ARDS, acute respiratory distress syndrome; BNP, brain natriuretic peptide; BMI, body mass index; BP, blood pressure; ECV, extracellular volume; eGFR, glomerular filtration rate estimated with the CKD-EPI formula and truncated at 90 ml/min/1.73 m²; LV, left ventricle; RV, right ventricle; T1, longitudinal relaxation time; T2, transversal relaxation time.

effects given the exploratory nature of the present study, and *p* < 0.05 were considered to reflect significant differences.

## RESULTS

Among the 222 COVID-19 patients hospitalized during the study period, 45 exhibited a peak troponin Ic > 50 ng/ml, and 19 fulfilled all study inclusion criteria. As detailed in **Table 2**, at the 1st CMR, the median age was 66 [59-71] years, and the median from peak troponin was 3.2 [2.6-3.9] months. Seventeen patients (89%) were male, 11 (58%) had previously been identified with hypertension or obesity (6 with obesity and 8 with hypertension), and as many as 16 (84%) had been affected by an acute respiratory distress syndrome (ARDS) requiring mechanical ventilation at the acute phase.

<table><caption>**TABLE 3** | Changes in clinical, CMR and blood parameters of the 13 patients who underwent the two CMRs at medians of 3 and 11 months from peak troponin respectively.</caption><thead><tr><th></th><th>1st CMR</th><th>2nd CMR</th><th>P-value</th></tr></thead><tbody><tr><td>BMI (kg/m²)</td><td>27.4 [25.4-31.9]</td><td>30.9 [28.8-33.60]</td><td>0.103</td></tr><tr><td>Heart rate (bpm)</td><td>77.0 [65.4-82.2]</td><td>64.1 [57.5-79.3]</td><td>0.046</td></tr><tr><td>Systolic BP (mmHg)</td><td>134 [125-145]</td><td>142 [127-156]</td><td>0.173</td></tr><tr><td>Diastolic BP (mmHg)</td><td>81 [72-85]</td><td>81 [77-90]</td><td>0.166</td></tr><tr><td>End-diastolic LV volume (mL/m²)</td><td>63 [53-71]</td><td>61 [51-69]</td><td>0.576</td></tr><tr><td>LV ejection fraction (%)</td><td>60 [53-65]</td><td>56 [52-62]</td><td>0.388</td></tr><tr><td>LV mass (g/m²)</td><td>70 [60-82]</td><td>68 [59-82]</td><td>0.419</td></tr><tr><td>LV mass/volume ratio</td><td>1.23 [1.06-1.26]</td><td>1.12 [1.02-1.34]</td><td>0.650</td></tr><tr><td>End-diastolic RV volume (mL/m²)</td><td>63 [53-71]</td><td>61 [51-69]</td><td>0.576</td></tr><tr><td>RV ejection fraction (%)</td><td>60 [53-65]</td><td>56 [52-62]</td><td>0.388</td></tr><tr><td>Myocardial T1 (ms)</td><td>1,257 [1,225-12,646]</td><td>1,233 [1,192-1,256]</td><td>0.038</td></tr><tr><td>Myocardial T2 (ms)</td><td>37.6 [35.9-39.5]</td><td>38.0 [36.5-40.5]</td><td>0.576</td></tr><tr><td>Myocardial ECV (%)</td><td>27.4 [25.7-31.1]</td><td>25.9 [23.1-27.3]</td><td>0.007</td></tr><tr><td>Delayed retention myocarditis pattern</td><td>2 (14%)</td><td>2 (14%)</td><td>1.000</td></tr><tr><td>Skeletal T1 (ms)</td><td>1,122 [1,104-1,173]</td><td>1,134 [1,104-1,228]</td><td>0.382</td></tr><tr><td>Skeletal ECV (%)</td><td>15.6 [14.2-19.2]</td><td>12.7 [12.2-14.9]</td><td>0.001</td></tr><tr><td>Hematocrit (%)</td><td>42.2 [40.1-43.4]</td><td>42.4 [39.2-44.5]</td><td>1.000</td></tr><tr><td>C Reactive Protein (mg/mL)</td><td>4 (4)</td><td>4 [4-9.3]</td><td>0.028</td></tr><tr><td>Troponin Ic (ng/ml)</td><td>5.5 [2.0-13.2]</td><td>5.0 [2.75-12.25]</td><td>0.893</td></tr><tr><td>Nt-pro BNP (pg/mL)</td><td>111 [41-133]</td><td>56 [35-52]</td><td>0.285</td></tr><tr><td>Albumin (g/L)</td><td>42.0 [40.3-47.4]</td><td>44.1 [42.7-46.0]</td><td>0.388</td></tr><tr><td>eGFR (ml/min/1.73 m²)</td><td>90 [87-90]</td><td>90 [82-90]</td><td>0.221</td></tr></tbody></table>

BMI, body mass index; BNP, brain natriuretic peptide; BP, blood pressure; ECV, extracellular volume; eGFR, glomerular filtration rate estimated with the CKD-EPI formula and truncated at 90 ml/min/1.73 m²; LV, left ventricle; RV, right ventricle; T1, longitudinal relaxation time; T2, transversal relaxation time.

## Baseline CMR

The 1st CMR, recorded at a median 3.2 [interquartile range: 2.6-3.9] months from the troponin peak, showed a > 50% LV ejection fraction in all but 2 patients for whom it was only slightly lower (46% and 48%). However, as many as 12 (63%) exhibited LV concentric remodeling (i.e., high LV mass/volume ratio), which was associated with LV hypertrophy (i.e., high LV mass) in 9 cases. Myocardial tissue damage was documented in 11 patients (58%), including 9 increased myocardial ECVs, 3 abnormal T1, 1 abnormal T2, and 2 evocative late gadolinium enhancements (LGE). No pattern suggestive of myocardial infarction was observed (i.e., no sub-endocardial or transmural LGE).

For the shoulder skeletal muscles, abnormal values were observed for T1 in 2 cases (11%) and for ECV in 14 (74%). As detailed in **Table 2**, most plasma analytics were within normal or sub-normal concentration ranges (Table 2), including troponin Ic (all ≤ 29 ng/mL), CRP (all ≤ 10 mg/mL), NT-proBNP (all < 450 pg/mL) and eGFR (all but one > 80 ml/min/1.73 m²).
Myocardial ECV (%)

<figure><img src="image_4.png" /></figure>

Skeletal muscle ECV (%)

<figure><img src="image_5.png" /></figure>

LV mass/volume ratio

<figure><img src="image_6.png" /></figure>

**FIGURE 2** | Individual variations between the 1st and 2nd CMR for the ECV from the myocardium and skeletal muscles, as well as for the LV mass/volume ratio, which was used to assess LV concentric remodeling and normalized to male values (i.e., with the values in women increased by 0.21 to compensate for the difference in the normal upper limits between women (0.90) and men (1.11)). The dashed lines represent the normal upper limits.

## Follow-Up CMR

The 2nd CMR was performed in 13 out of the 19 patients, at a median of 11.1 [11.0–11.7] months from peak troponin. LV function and remodeling parameters were unchanged between the 1st and 2nd CMR, but significant decreases in heart rate, myocardial T1, and particularly ECV from skeletal muscles and myocardium were observed (Table 3, Figure 2). Late contrast enhancement was still documented in 2 patients, and as evidenced in Figure 2, there was a return to normal or below the normal range for all ECVs of the myocardium and skeletal muscles.

## DISCUSSION

As illustrated by a schematic representation in Figure 3, a frequent increase in ECV affecting the myocardium and skeletal muscles and which regressed during the first year, constituted the main observation in our consecutive series of patients with no prior history of cardiac disease but for whom COVID-19 induced myocardial damage was ascertained by a significant rise in blood troponin Ic. A COVID-19 etiology of these increased ECV values is supported by their return to normal or below the normal range at 1 year (Figure 2), in contrast to the stability observed for other CMR parameters. This ECV evolution likely reflects the resolution of the extracellular interstitial edema, which is commonly observed in the heart and other organs in COVID-19 autopsy studies (26, 27).

CMR already documented an increased myocardial ECV at the acute or sub-acute phase of COVID-19 and associated with increases in myocardial T1 and T2 (5, 6). This observation was attributed to inflammatory edema at the time. Our serial CMR data show that this increased ECV: (i) also affects skeletal muscles, (ii) resolves very progressively, given its common persistence at a median of 3 months from the acute phase (i.e., at the time of the 1st CMR), and (iii) is then no longer associated with any evident signs of active damage or inflammation (i.e., based on the normal or below the normal range of CRP, troponin and myocardial T2 values).

Interestingly, the decrease in ECV at 1 year was observed in our COVID patients irrespective of the presence or absence

Myocardial extra-cellular volume

<figure><img src="image_7.png" /></figure>

**FIGURE 3** | Schematic representation of the progressive decrease during the first year of the myocardial ECV, presumably in line with a delayed resolution of the interstitial edema.

of an abnormal ECV at 3-months (see Figure 2). This decrease might thus be commonly involved in the recovery of severe COVID-19. In addition, a possible role of a non-specific response associated with ARDS needs further investigation. Indeed, 84% of our COVID-19 patients presented an ARDS at the acute phase, and ARDS patients are commonly affected by muscle dysfunction in both early and late stages, constituting a significant morbidity factor (28, 29).

This increased ECV was not associated with any evident deterioration of cardiac function, with LV ejection fractions and volumes remaining normal or below the normal range during follow-up according to the CMR, as well as the echocardiography data (see **Supplementary Data File**). As many as 63% of our patients were affected by LV concentric remodeling, an indicator of increased cardiovascular risk (15, 16). However, this remodeling was unchanged between the two evaluations, and it may constitute an underlying pathology due to the risk factors shared by concentric remodeling and severe COVID-19 (age, obesity, hypertension).
A main limitation is the small sample size of the present study population, and further studies will be required to confirm the results.

## Conclusion and Perspectives

The present serial CMR study shows a slow return to normal of the extracellular volume of the myocardium and skeletal muscles in many patients with no history of cardiac disease, but for whom an increase in blood troponin-Ic ascertained COVID-19 induced myocardial damage. This observation is likely due to a delayed resolution of the interstitial edema, which is known to affect severe COVID-19 patients. Associations with long-COVID symptoms (30) need to be investigated on a larger scale. This might help to better understand and perhaps to prevent or treat these symptoms. The potential role of a non-specific response associated with ARDS also requires further investigation.

## DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

## ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Ethics Committee of the Nancy University Hospital. Written informed consent for participation was not required for this study

in accordance with the national legislation and the institutional requirements.

## AUTHOR CONTRIBUTIONS

Seven authors contributed significantly to the analysis and interpretation of the data (LF, M-SR, NJ, J-SL, GH, OH, and P-YM), and/or to the writing or revision of the manuscript (LF, NP, J-SL, OH, and P-YM), the four others collaborated in the study implementation, and/or management of the included subjects (DM, FG, NP, and CS-S). All authors contributed to the article and approved the submitted version.

## FUNDING

This study was funded by CHRU-Nancy, Nancy, France. Hospital's own funds were used for the study organization.

## ACKNOWLEDGMENTS

The authors wish to thank Aboubaker Cherifi for his help in the organization of the study and Dr. Petra Neufing for critical review of the manuscript.

## SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm.2022.831580/full#supplementary-material

## REFERENCES

1. Maccio U, Zinkernagel AS, Shambat SM, Zeng X, Cathomas G, Ruschitzka F, et al. SARS-CoV-2 leads to a small vessel endotheliitis in the heart. *EBioMedicine*. (202) 63:103182. doi: 10.1016/j.ebiom.2020.103182

2. Puntmann VO, Carerj ML, Wieters I, Fahim M, Arendt C, Hoffmann J, et al. Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19). *JAMA Cardiol*. (2020) 5:1265-73. doi: 10.1001/jamacardio.2020.3557

3. Filippetti L, Pace N, Marie PY. Cardiac Involvement After Recovering From COVID-19. *JAMA Cardiol*. (2021) 6:243-4. doi: 10.1001/jamacardio.2020.5279

4. Freaney PM, Shah SJ, Khan SS. COVID-19 and Heart Failure With Preserved Ejection Fraction. *JAMA*. (2020) 324:1499-500. doi: 10.1001/jama.2020.17445

5. Chen BH, Shi NN, Wu CW, An DA, Shi YX, Wesemann LD, et al. Early cardiac involvement in patients with acute COVID-19 infection identified by multiparametric cardiovascular magnetic resonance imaging. *Eur Heart J Cardiovasc Imaging*. (2021) 22:844-51. doi: 10.1093/ehjci/jeab042

6. Huang L, Zhao P, Tang D, Zhu T, Han R, Zhan C, et al. Cardiac Involvement in Patients Recovered From COVID-19 Identified Using Magnetic Resonance Imaging. *JACC Cardiovasc Imaging*. (2020) 13:2330-9. doi: 10.1016/j.jcmg.2020.05.004

7. Doeblin P, Kelle S. Going after COVID-19 myocarditis. *Eur Heart J Cardiovasc Imaging*. (2021) 22:852-4. doi: 10.1093/ehjci/jeab097

8. Ramani SL, Samet J, Franz CK, Hsieh C, Nguyen CV, Horbinski C, et al. Musculoskeletal involvement of COVID-19: review of imaging. *Skeletal Radiol*. (2021) 50:1763-73. doi: 10.1007/s00256-021-03734-7

9. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr*. (2015) 28:1-39. doi: 10.1016/j.echo.2014.10.003

10. Nagueh SF, Smiseth OA, Appleton CP, Byrd BF 3rd, Dokainish H, Edvardsen T, et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *Eur Heart J Cardiovasc Imaging*. (2016) 17:1321-60. doi: 10.1093/ehjci/jew082

11. Vincenti G, Monney P, Chaptinel J, Rutz T, Coppo S, Zenge MO, et al. Compressed sensing single-breath-hold CMR for fast quantification of LV function, volumes, and mass. *JACC Cardiovasc Imaging*. (2014) 7:882-92. doi: 10.1016/j.jcmg.2014.04.016

12. Ferreira VM, Schulz-Menger J, Holmvang G, Kramer CM, Carbone I, Sechtem U, et al. Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. *J Am Coll Cardiol*. (2018) 72:3158-76. doi: 10.1016/j.jacc.2018.09.072

13. Muehlberg F, Arnhold K, Fritsch S, Funk S, Prothmann M, Kermer J, et al. Comparison of fast multi-slice and standard segmented techniques for detection of late gadolinium enhancement in ischemic and non-ischemic cardiomyopathy - a prospective clinical cardiovascular magnetic resonance trial. *J Cardiovasc Magn Reson*. (2018) 20:13. doi: 10.1186/s12968-018-0434-2

14. Marie PY, Mandry D, Huttin O, Micard E, Bonnemains L, Girerd N, et al. Comprehensive monitoring of cardiac remodeling with aortic stroke volume values provided by a phase-contrast CMR sequence. *J Hypertens*. (2016) 34:967-73. doi: 10.1097/HJH.0000000000000889

15. Tsao CW, Gona PN, Salton CJ, Chuang ML, Levy D, Manning WJ, et al. Left Ventricular Structure and Risk of Cardiovascular Events: A Framingham Heart Study Cardiac Magnetic Resonance Study. *J Am Heart Assoc*. (2015) 4:e002188. doi: 10.1161/JAHA.115.002188

16. Bluemke DA, Kronmal RA, Lima JA, Liu K, Olson J, Burke GL, et al. The relationship of left ventricular mass and geometry to incident cardiovascular
events: the MESA (Multi-Ethnic Study of Atherosclerosis) study. *J Am Coll Cardiol.* (2008) 52:2148–55. doi: 10.1016/j.jacc.2008.09.014

17. Huber AT, Bravetti M, Lamy J, Bacoyannis T, Roux C, de Cesare A, et al. Non-invasive differentiation of idiopathic inflammatory myopathy with cardiac involvement from acute viral myocarditis using cardiovascular magnetic resonance imaging T1 and T2 mapping. *J Cardiovasc Magn Reason.* (2018) 20:11. doi: 10.1186/s12968-018-0430-6

18. Aquaro GD, Camastra G, Monti L, Lombardi M, Pepe A, Castelletti S, et al. Reference values of cardiac volumes, dimensions, and new functional parameters by MR: A multicenter, multivendor study. *J Magn Reson Imaging.* (2017) 45:1055–67. doi: 10.1002/jmri.25450

19. Chuang ML, Gona P, Hautvast GL, Salton CJ, Breeuwer M, O'Donnell CJ, et al. CMR reference values for left ventricular volumes, mass, and ejection fraction using computer-aided analysis: the Framingham Heart Study. *J Magn Reson Imaging.* (2014) 39:895–900. doi: 10.1002/jmri.24239

20. Eng J, McClelland RL, Gomes AS, Hundley WG, Cheng S, Wu CO, et al. Adverse Left Ventricular Remodeling and Age Assessed with Cardiac MR Imaging: The Multi-Ethnic Study of Atherosclerosis. *Radiology.* (2016) 278:714–22. doi: 10.1148/radiol.2015150982

21. Constant Dit Beaufils AL, Huttin O, Jobbe-Duval A, Senage T, Filippetti L, Piriou N, et al. Replacement Myocardial Fibrosis in Patients With Mitral Valve Prolapse: Relation to Mitral Regurgitation, Ventricular Remodeling, and Arrhythmia. *Circulation.* (2021) 143:1763–74. doi: 10.1161/CIRCULATIONAHA.120.050214

22. Wang X, Joseph AA, Kalentev O, Merboldt KD, Voit D, Roeloffs VB, et al. High-resolution myocardial T1 mapping using single-shot inversion-recovery fast low-angle shot CMR with radial undersampling and iterative reconstruction. *Br J Radiol.* (2016) 89:20160255. doi: 10.1259/bjr.20160255

23. Thavendiranathan P, Zhang L, Zafar A, Drobni ZD, Mahmood SS, Cabral M, et al. Myocardial T1 and T2 Mapping by Magnetic Resonance in Patients With Immune Checkpoint Inhibitor-Associated Myocarditis. *J Am Coll Cardiol.* (2021) 77:1503–16. doi: 10.1016/j.jacc.2021.01.050

24. van Heeswijk RB, Feliciano H, Bongard C, Bonanno G, Coppo S, Lauriers N, et al. Free-breathing 3 T magnetic resonance T2-mapping of the heart. *JACC Cardiovasc Imaging.* (2012) 5:1231–9. doi: 10.1016/j.jcmg.2012.06.010

25. Soler R, Méndez C, Rodríguez E, Barriales R, Ochoa JP, Monserrat L. Phenotypes of hypertrophic cardiomyopathy. An illustrative review of

CMR findings. *Insights Imaging.* (2018) 9:1007–20. doi: 10.1007/s13244-018-0656-8

26. Haslbauer JD, Tzankov A, Mertz KD, Schwab N, Nienhold R, Twerenbold R, et al. Characterisation of cardiac pathology in 23 autopsies of lethal COVID-19. *J Pathol Clin Res.* (2021) 7:326–37. doi: 10.1002/cjp2.212

27. Mondello C, Roccuzzo S, Malfa O, Sapienza D, Gualniera P, Ventura Spagnolo E, et al. Pathological Findings in COVID-19 as a Tool to Define SARS-CoV-2 Pathogenesis A Systematic Review. *Front Pharmacol.* (2021) 12:614586. doi: 10.3389/fphar.2021.614586

28. Files DC, Sanchez MA, Morris PE. A conceptual framework: the early and late phases of skeletal muscle dysfunction in the acute respiratory distress syndrome. *Crit Care.* (2015) 19:266. doi: 10.1186/s13054-015-0979-5

29. Matthay MA, Zemans RL, Zimmerman GA, Arabi YM, Beitler JR, Mercat A, et al. Acute respiratory distress syndrome. *Nat Rev Dis Primers.* (2019) 5:18. doi: 10.1038/s41572-019-0069-0

30. Yan Z, Yang M, Lai CL. Long COVID-19 Syndrome: A Comprehensive Review of Its Effect on Various Organ Systems and Recommendation on Rehabilitation Plans. *Biomedicines.* (2021) 9:966. doi: 10.3390/biomedicines9080966

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Filippetti, Pace, Louis, Mandry, Goehringer, Rocher, Jay, Selton-Suty, Hossu, Huttin and Marie. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.